Modulation of transforming growth factor‑β signaling transducers in colon adenocarcinoma cells induced by staphylococcal enterotoxin B

Akbari,Abolfazl; Mobini,Gholam Reza; Maghsoudi,Reza; Akhtari,Javad; Faghihloo,Ebrahim; Farahnejad,Zohreh

doi:10.3892/mmr.2015.4596

Modulation of transforming growth factor‑β signaling transducers in colon adenocarcinoma cells induced by staphylococcal enterotoxin B

Authors:
- Abolfazl Akbari
- Gholam Reza Mobini
- Reza Maghsoudi
- Javad Akhtari
- Ebrahim Faghihloo
- Zohreh Farahnejad
View Affiliations

Affiliations: Colorectal Research Center, Iran University of Medical Sciences, Tehran 1313114456, Iran, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran, Department of Microbiology and Immunology, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran, Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari 48175866, Iran, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran 1313114456, Iran, Department of Medical Mycology, AJA University of Medical Sciences, Tehran 1917793164, Iran
Published online on: November 23, 2015 https://doi.org/10.3892/mmr.2015.4596
Pages: 909-914

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is a notable cause of cancer‑associated mortality worldwide, making it a pertinent topic for the study of cancer and its treatment. Staphylococcal enterotoxin B (SEB), an enterotoxin produced by Staphylococcus aureus, has been demonstrated to exert anticancer and antimetastatic effects due to its ability to modify cell immunity and cellular signaling pathways. In the current study, SEB was investigated, including whether it exerts its growth inhibitory effects on colon adenocarcinoma cells. This may occur through the manipulation of a key tumor growth factor, termed transforming growth factor‑β (TGF‑β), and its signaling pathway transducer, Smad2/3. The human colon adenocarcinoma HCT116 cell line was treated with different concentrations of SEB, and cell number was measured using MTT assay at different treatment times. Smad2/3 RNA expression level was analyzed in untreated or SEB‑treated cells using quantitative polymerase chain reaction, which indicated significant differences between cell viability and Smad2/3 expression levels. SEB effectively downregulated Smad2/3 expression in the HCT116 cells at concentrations of 1 and 2 µg/ml (P=0.0021 and P=0.0017, respectively). SEB concentrations that were effective at inhibiting Smad2/3 expression were correlated with those able to inhibit the proliferation of the cancer cells. SEB inhibited Smad2/3 expression at the mRNA level in a concentration‑ and time‑dependent manner. The present study thus proposed SEB as an agent able to significantly reduce Smad2/3 expression in colon cancer cells, provoking moderate TGF‑β growth signaling and the reduction of tumor cell proliferation.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Carmona FJ and Esteller M: Epigenomics of human colon cancer. Mutat Res. 693:53–60. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kim E, Coelho D and Blachier F: Review of the association between meat consumption and risk of colorectal cancer. Nutr Res. 33:983–994. 2013. View Article : Google Scholar : PubMed/NCBI
4	Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013. View Article : Google Scholar :
5	Mohan HM, O'Connor DB, O'Riordan JM and Winter DC: Prognostic significance of detection of microscopic peritoneal disease in colorectal cancer: A systematic review. Surg Oncol. 22:e1–6. 2013. View Article : Google Scholar : PubMed/NCBI
6	Loh KW, Majid HA, Dahlui M, Roslani AC and Su TT: Sociodemographic predictors of recall and recognition of colorectal cancer symptoms and anticipated delay in help-seeking in a multiethnic asian population. Asian Pac J Cancer Prev. 14:3799–3804. 2013. View Article : Google Scholar
7	Ma J, Gao HM, Hua X, Lu ZY and Gao HC: Role of TGF-β1 in human colorectal cancer and effects after cantharidinate intervention. Asian Pac J Cancer Prev. 15:4045–4048. 2014. View Article : Google Scholar
8	Bierie B and Moses HL: TGF-β and cancer. Cytokine Growth Factor Rev. 17:29–40. 2006. View Article : Google Scholar
9	Jean-Jacques L: The dual role of TGF in human cancer: From tumor suppression to cancer metastasis. ISRN Mol Biol. 7:1–28. 2012.
10	Bierie B and Moses HL: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ramasamy S, Nattarayan V, Jayaraj GG, Arulanandh MD and Jaiswal A: Bacterial infection-mediated anticancer activity (BIMAc) - revisiting the molecular mechanisms. J Med Hypoth Ideas. 6:19–22. 2012. View Article : Google Scholar
12	Nauts HC, Fowler GA and Bogatko FH: A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Medica Scandinavica. 276:1–103. 1953.
13	Nauts HC: The beneficial effects of bacterial infections on host resistance to cancer: End result in 449 cases. (Monograph no. 8). 2nd edition. Cancer Research Institute; New York, NY, USA: 1980
14	Zacharski LR and Sukhatme VP: Coley's toxin revisited: Immunotherapy or plasminogen activator therapy of cancer? J Thromb Haemost. 3:424–427. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hoption Cann SA, van Netten JP and van Netten C: Dr William Coley and tumour regression: A place in history or in the future. Postgrad Med J. 79:672–680. 2003.
16	Zhong L, Zhang X and Covasa M: Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J Gastroenterol. 20:7878–7886. 2014. View Article : Google Scholar : PubMed/NCBI
17	Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B and Das BK: Bacteria in cancer therapy: A novel experimental strategy. J Biomed Sci. 17:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
18	Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G and Gress T: Claudin-4: A new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology. 121:678–684. 2001. View Article : Google Scholar : PubMed/NCBI
19	Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P and Sukumar S: Clostridium perfringensenterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol. 164:1627–1633. 2004. View Article : Google Scholar : PubMed/NCBI
20	Gao Z and McClane BA: Use of Clostridium perfringens enterotoxin and the enterotoxin receptor-binding domain (C-CPE) for cancer treatment: Opportunities and challenges. J Toxicol. 2012:9816262012. View Article : Google Scholar
21	Ansiaux R and Gallez B: Use of botulinum toxins in cancer therapy. Expert Opin Investig Drugs. 16:209–218. 2007. View Article : Google Scholar : PubMed/NCBI
22	Mahmoodzadeh Hosseini H, Ali Imani Fooladi A, Soleimanirad J, Reza Nourani M and Mahdavi M: Exosome/staphylococcal enterotoxin B, an anti tumor compound against pancreatic cancer. J BUON. 19:440–448. 2014.PubMed/NCBI
23	Hui J, Xiao F, Li H, Cui X, Liu H and Hu F: Inhibiting tumor-cell growth by novel truncated staphylococcal enterotoxin C2 mutant. Sheng Wu Gong Cheng Xue Bao. 27:891–899. 2011.PubMed/NCBI
24	Reis LO, Ferreira U, Billis A, Cagnon VH and Fávaro WJ: Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 187:438–445. 2012. View Article : Google Scholar
25	Dohlsten M, Hedlund G, Segren S, Lando PA, Herrmann T, Kelly AP and Kalland T: Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: Evidence for a novel enterotoxin receptor. Eur J Immunol. 21:1229–1233. 1991. View Article : Google Scholar : PubMed/NCBI
26	Fuller CL and Braciale VL: Selective induction of CD8⁺ cytotoxic T lymphocyte effector function by Staphylococcus enterotoxin B. J Immunol. 161:5179–5186. 1998.PubMed/NCBI
27	Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M and Montecucco C: Anthrax toxin: A tripartite lethal combination. FEBS Lett. 531:384–388. 2002. View Article : Google Scholar : PubMed/NCBI
28	Engedal N, Skotland T, Torgersen ML and Sandvig K: Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol. 4:32–46. 2011. View Article : Google Scholar : PubMed/NCBI
29	Bandala C, Perez-Santos JL, Lara-Padilla E, Delgado Lopez G and Anaya-Ruiz M: Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac J Cancer Prev. 14:891–894. 2013. View Article : Google Scholar : PubMed/NCBI
30	Brigotti M, Arfilli V, Carnicelli D, Rocchi L, Calcabrini C, Ricci F, Pagliaro P, Tazzari PL, Alfieri RR, Petronini PG and Sestili P: Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells. Toxins (Basel). 5:431–444. 2013. View Article : Google Scholar